Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis

Journal of Immunotoxicology

Volumn 5, Issue 2, 2008, Pages 189-199

  Dahlén, Eva ^a   Barchan, Karin ^a   Herrlander, Daniel ^a   Höjman, Patrik ^a   Karlsson, Marie ^a   Ljung, Lill ^a   Andersson, Mats ^a   Bäckman, Eva ^a,d   Hager, Ann Christin Malmborg ^a   Walse, Bjorn ^b   Joosten, Leo ^c   Van Den Berg, Wim ^c  

^a Alligator Bioscience AB   (Sweden)

^b SARomics AB   (Sweden)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Creo Dynamics AB   (Sweden)

Author keywords

Arthritis; Directed evolution; Interleukin 1; Interleukin 1 receptor antagonist; Mutants

Indexed keywords

ARGININE; ASPARAGINE; ASPARTIC ACID; COLLAGEN; GLUTAMIC ACID; GLUTAMINE; HISTIDINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEUCINE; METHIONINE; PROLINE; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTAGONISTIC ACTIVITY; ARTHRITIS; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; DNA RECOMBINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PURIFICATION; DRUG SCREENING; DRUG STRUCTURE; GENE LIBRARY; GENE MUTATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS;

AMINO ACID SUBSTITUTION; ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL LINE; DIRECTED MOLECULAR EVOLUTION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MICE; MICE, INBRED DBA; MUTATION, MISSENSE; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, INTERLEUKIN-1;

MUS;

EID: 45849135653     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910802131477     Document Type: Article

References (36)

1. Arend, W. P., and Gabay, C. 2000. Physiologic role of interleukin-1 receptor antagonist. Arthritis Res. 2:245-248.
2. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (Eds.) 2002. Short Protocols in Molecular Biology. Hoboken NJ: Wiley.
3. Bodar, E. J., van der Hilst, J. C., Drenth, J. P., van Der Meer, J. W., and Simon, A. 2005. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: Introducing a vaccination provocation model. Neth. J. Med. 63:260-264.
4. Bowen, S., Tare, N., Inoue, T., Yamasaki, M., Okabe, M., Horii, I., and Eliason, J. F. 1999. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp. Hematol. 27: 425-432.
5. Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., Watt, I., Williams, B., Aitchison, R., McCabe, D., and Musikic, P. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41:2196-2204.
6. Burger, D., Dayer, J. M., Palmer, G., and Gabay, C. 2006. Is IL-1 a good therapeutic target in the treatment of arthritis? Best. Pract. Res. Clin. Rheumatol. 20:879-896.
7. Chae, J. J., Wood, G., Masters, S. L., Richard, K., Park, G., Smith, B. J., and Kastner, D. L. 2006. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc. Natl. Acad. Sci. USA 103:9982-9987.
8. Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., and McCabe, D. 2002. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:614-624.
9. Cohen, S. B., Moreland, L. W., Cush, J. J., Greenwald, M. W., Block, S., Shergy, W. J., Hanrahan, P. S., Kraishi, M. M., Patel, A., Sun, G., and Bear, M. B. 2004. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63:1062-1068.
10. Delano. 2002. The PyMol Molecular Graphics System. Delano Scientific, San Carlos.
11. Dierselhuis, M. P., Frenkel, J., Wulffraat, N. M., and Boelens, J. J. 2005. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 44:406-408.
12. Dinarello, C. A. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095-2147.
13. Dinarello, C. A. 2000. Pro-inflammatory cytokines. Chest 118:503-508.
14. Dinarello, C. A. 2002. The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 20:S1-13.
15. Fitzgerald, A. A., Leclercq, S. A., Yan, A., Homik, J. E., and Dinarello, C. A. 2005. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52:1794-1803.
16. Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., Hill, S., Turner, M. L., Karp, B. I., Aksentijevich, I., Pucino, F., Penzak, S. R., Haverkamp, M. H., Stein, L., Adams, B. S., Moore, T. L., Fuhlbrigge, R. C., Shaham, B., Jarvis, J. N., O'Neil, K., Vehe, R. K., Beitz, L. O., Gardner, G., Hannan, W. P., Warren, R. W., Horn, W., Cole, J. L., Paul, S. M., Hawkins, P. N., Pham, T. H., Snyder, C., Wesley, R. A., Hoffmann, S. C., Holland, S. M., Butman, J. A., and Kastner, D. L. 2006. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. New Engl. J. Med. 355:581-592.
17. Hawkins, P. N., Bybee, A., Aganna, E., and McDermott, M. F. 2004a. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 50:2708-2709.
18. Hawkins, P. N., Lachmann, H. J., Aganna, E., and McDermott, M. F. 2004b. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50:607-612.
19. Hawkins, P. N., Lachmann, H. J., and McDermott, M. F. 2003. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. New Engl. J. Med. 348:2583-2584.
20. Heguy, A., Baldari, C. T., Macchia, G., Telford, J. L., and Melli, M. 1992. Amino acids conserved in interleukin-1 receptors (IL-1Rs) and the Drosophila toll protein are essential for IL-1R signal transduction. J. Biol. Chem. 267:2605-2609.
21. Hoffman, H. M., and Firestein, G. S. 2006. Anakinra for the treatment of neonatal-onset multisystem inflammatory disease. Nat. Clin. Pract. Rheumatol. 2:646-647.
22. Hoffman, H. M., Rosengren, S., Boyle, D. L., Cho, J. Y., Nayar, J., Mueller, J. L., Anderson, J. P., Wanderer, A. A., and Firestein, G. S. 2004. Prevention of cold-associated acute inflammation in familial cold auto-inflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779-1785.
23. Joosten, L. A., Helsen, M. M., Saxne, T., van De Loo, F. A., Heinegard, D., and van den Berg, W. B. 1999. IL-1αβ blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNFα blockade only ameliorates joint inflammation. J. Immunol. 163:5049-5055.
24. Larsen, C. M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., and Donath, M. Y. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New Engl. J. Med. 356:1517-1526.
25. Nixon, R., Bansback, N., and Brennan, A. 2007. The efficacy of inhibiting tumour necrosis factor-α and interleukin 1 in patients with rheumatoid arthritis: A meta-analysis and adjusted indirect comparisons. Rheumatology 46:1140-1147.
26. Nuki, G., Bresnihan, B., Bear, M. B., and McCabe, D. 2002. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:2838-2846.
27. Paget, S. A. 2002. Efficacy of anakinra in bone: Comparison to other biologics. Adv. Ther. 19:27-39.
28. Pascual, V., Allantaz, F., Arce, E., Punaro, M., and Banchereau, J. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201:1479-1486.
29. Patten, P. A., Howard, R. J., and Stemmer, W. P. 1997. Applications of DNA shuffling to pharmaceuticals and vaccines. Curr. Opin. Biotechnol. 8:724-733.
30. Radons, J., Gabler, S., Wesche, H., Korherr, C., Hofmeister, R., and Falk, W. 2002. Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling. J. Biol. Chem. 277:16456-16463.
31. Rudinskaya, A., and Trock, D. H. 2003. Successful treatment of a patient with refractory adult-onset still disease with anakinra. J. Clin. Rheumatol. 9:330-332.
32. Ruiz, P. J., Masliah, E., Doherty, T. A., Quach, A., and Firestein, G. S. 2007. Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinra. Ann. Rheum. Dis. 66: 422-423.
33. Schreuder, H., Tardif, C., Trump-Kallmeyer, S., Soffientini, A., Sarubbi, E., Akeson, A., Bowlin, T., Yanofsky, S., and Barrett, R. W. 1997. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 386:194-200.
34. Stylianou, E., O'Neill, L. A., Rawlinson, L., Edbrooke, M. R., Woo, P., and Saklatvala, J. 1992. Interleukin-1 induces NF-κB through its type I but not its type II receptor in lymphocytes. J Biol Chem 267:15836-15841.
35. Vasques Godinho, F. M., Parreira Santos, M. J., and Canas da Silva, J. 2005. Refractory adult onset Still's disease successfully treated with anakinra. Ann. Rheum. Dis. 64:647-648.
36. Yuan, L., Kurek, I., English, J., and Keenan, R. 2005. Laboratory-directed protein evolution. Microbiol. Mol. Biol. Rev. 69:373-392.